What Apertus Pharmaceuticals does

Apertus Pharmaceuticals, LLC is a privately-held contract development and manufacturing organization (CDMO) founded in 2012 and headquartered in St. Louis, Missouri. The company provides integrated pharmaceutical development and manufacturing services spanning active pharmaceutical ingredient (API) synthesis and sourcing, formulation development, analytical method development and validation, and cGMP contract manufacturing of finished dosage forms including tablets, capsules, suppositories, creams, and liquids. Distinctive capabilities include DEA registration for Schedule II-V controlled substance manufacturing, an FDA-inspected cGMP facility with Voluntary Action Indicated (VAI) status from a January 2020 audit, in-house serialization using Optel equipment, and small-to-medium batch production that targets a niche between large CMOs and academic laboratories. The company is co-founded and led by Dr. David Gindelberger (CEO, PhD organometallic chemistry from UC Berkeley, 28+ years industry experience, 21 patents) and Dr. Rick L. Ryan (Board Chairman, PhD biochemistry, 30+ years in life sciences including executive roles at Millipore and Monsanto).

Apertus operates on a fee-for-service, project-based revenue model with pricing negotiated per engagement based on scope, volume, and complexity. Go-to-market is direct B2B enterprise sales targeting pharmaceutical companies, small biotech and startup firms (particularly in the St. Louis area), and OTC/cosmetic manufacturers. The company is also registered as a device manufacturer, expanding its addressable service surface. Customer relationships are managed through a collaborative sales approach emphasizing regular contact, open communication, and full disclosure of project progress to enable rapid decision making. Distribution is exclusively direct, with no intermediaries, and Apertus maintains two facilities in Missouri: a primary manufacturing and operational site in Maryland Heights and a secondary office in Ballwin. The company has operated since founding on a single $700,000 BioGenerator investment in 2012, with no subsequent institutional funding rounds disclosed, suggesting a bootstrapped, founder-controlled operating model.

In March 2026, Apertus entered a strategic partnership with the nonprofit API Innovation Center (APIIC) to apply continuous manufacturing technology to lomustine, a chemotherapy drug, at its Missouri facility. Under this model, APIIC covers upfront capital costs of continuous production equipment placed at Apertus's site, reducing the financial risk of adopting advanced manufacturing technologies and positioning the company to participate in federally-aligned domestic pharmaceutical supply chain initiatives.

Name

Apertus Pharmaceuticals

Legal name

Apertus Pharmaceuticals, LLC

Website

https://apertuspharma.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Apertus Pharmaceuticals is a St. Louis-based contract development and manufacturing organization (CDMO) providing integrated API synthesis, formulation development, analytical services, and cGMP manufacturing (including DEA Schedule II-V controlled substances) to pharmaceutical, biotech, and OTC clients.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ)

Keywords

• Contract pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Formulation development services
• CGMP drug production
• Analytical method development

Headquarters

HQ city

St Louis

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Fee-for-service contract manufacturing for pharmaceutical products. Customers engage Apertus for development and/or manufacture of capsule, tablet, cream, liquid and suppository products. Revenue generated through project-based contracts for cGMP manufacturing, analytical services, and tech transfer.
2. API Development and Manufacturing: Services for API sourcing, synthesis, route optimization, cGMP synthesis for pre-clinical and clinical studies, and NCE manufacturing. Revenue from process development projects and API manufacturing contracts.
3. Analytical Development Services: Method development, validation, and transfer services. Includes stability studies, forced degradation studies, and clean-out protocols. Billed as professional services engagements.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Core offering

Apertus Pharmaceuticals is a contract development and manufacturing organization (CDMO) that provides integrated pharmaceutical services spanning active pharmaceutical ingredient (API) sourcing and cGMP synthesis, formulation development (tablets, capsules, suppositories, creams, liquids), analytical method development and release testing, and FDA-inspected cGMP contract manufacturing of small-to-medium batch prescription drug products. The company is DEA-registered for Schedule II-V controlled substances and operates a single FDA-inspected facility in St. Louis, Missouri.

Product overview

Apertus Pharmaceuticals is a contract pharmaceutical development and manufacturing organization (CDMO) offering an integrated suite of services spanning the drug development lifecycle. The portfolio includes API Services (sourcing, synthesis, and cGMP manufacturing of active pharmaceutical ingredients), Formulation Development (solid dosage and analytical method development), Contract Manufacturing (FDA-inspected cGMP production of tablets, capsules, suppositories, creams, and liquids), and Analytical Development (release testing and method validation). These services work together to support clients from early-stage API development through commercial manufacturing, with capabilities including DEA Schedule II-V controlled substance handling and in-house serialization.

Differentiator

Problem solved

Functional benefit

Products and services

• API Services
• Formulation Development Collaborative formulation development services covering de-formulation studies (literature/IP review, API availability review, dissolution studies, blend compatibility), solid dosage formulation (tablets, capsules, suppositories) including pilot scale manufacturing and small scale engineering runs, analytical method development (HPLC, GC, wet bench testing), method validation and transfer, and accelerated and normal stability protocol design and execution.
• Contract Manufacturing FDA-inspected cGMP contract manufacturing of prescription drug products including tablets, capsules, suppositories, creams and liquids in small to medium sized batches at the company's Saint Louis facility. Capabilities include in-house serialization using an Optel Carton Serialization and Aggregation Workstation, in-house release testing for raw materials and finished goods, custom suppository shell printing and forming, device manufacturing under facility registration, and DEA Schedule II-V controlled substance manufacturing (currently Analytical and R&D registrations, with prior Schedule I-V Manufacturing registration renewable on customer request).
• Analytical Development Internal release testing and analytical method development services including HPLC, GC, dissolution testing, titrations, multinuclear NMR, particle size measurement, and X-ray analysis (powder and single crystal). Supports method development, validation and transfer, stability studies, forced degradation studies and clean-out protocols for pharmaceutical and biotech clients.

Quantifiable outcome

• Successfully completed FDA audit in January 2020
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Two partnerships are on record, tiered core and minor.

• API Innovation Center (APIIC)coreStrategic or Co-development Partner · 10 March 2026APIIC is a nonprofit working to modernize U.S. pharmaceutical manufacturing by covering upfront capital costs that prevent manufacturers from adopting continuous production technologies. Apertus Pharmaceuticals is partnered with APIIC to apply this model to lomustine, a chemotherapy drug, at a Missouri facility. APIIC develops continuous manufacturing processes and places required equipment at Apertus's facility without selling it, reducing financial risk of adopting new technology.
• Sentio BioSciencesminorStrategic or Co-development Partner · 10 March 2026Sentio BioSciences is working with APIIC on two additional active pharmaceutical ingredients (APIs). This partnership demonstrates APIIC's model being applied across multiple manufacturers to prove that removing upfront financial barriers can enable safer and more efficient domestic production.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Alcami Corporation: Alcami is a US-based small-to-mid-scale CDMO offering API manufacturing, formulation development, and cGMP drug product manufacturing. Directly comparable as a similarly sized domestic CDMO competing for the same biotech and specialty pharma projects.
• Metrics Contract Services: Metrics (a division of Mayne Pharma) is a US CDMO specializing in solid oral dose, topical, and small-batch prescription manufacturing. Highly comparable to Apertus's specialty solid-dose and small-to-medium batch contract manufacturing focus.
• Cambrex: Cambrex (acquired by Permira) is a leading small-molecule API and drug product CDMO with extensive DEA-controlled substance capabilities. Directly comparable along API synthesis, controlled substance manufacturing, and analytical services.
• Norwich Pharma Services: Norwich is a US-based CDMO offering API development, formulation, and cGMP manufacturing of solid, liquid, and topical dosage forms. Closely comparable mid-sized domestic CDMO with similar service breadth.
• Halo Pharma: Halo Pharma (formerly Halo Pharmaceutical) is a US CDMO focused on small-batch cGMP manufacturing of solid, liquid, and semi-solid dosage forms. Directly comparable niche focus on small-to-medium batch prescription manufacturing.

Broad incumbents

• Patheon (Thermo Fisher Scientific): Patheon, part of Thermo Fisher's pharma services, is one of the largest global CDMOs offering API, drug product, and analytical services across all scales. A broader incumbent that competes for many of the same pharmaceutical customers but at much larger scale.
• PCI Pharma Services: PCI is a global CDMO offering drug development, manufacturing, and packaging services including potent handling and serialization. Comparable along contract manufacturing and serialization capabilities but operates at significantly larger scale.
• Aptuit (Evotec): Aptuit, now part of Evotec, offers integrated drug discovery, API development, and cGMP manufacturing. Comparable as a vertically integrated CDMO with API-to-drug-product capabilities, though at much larger scale and broader geographic footprint.
• Curia (formerly AMRI): Curia (formerly Albany Molecular Research / AMRI) is a global CDMO offering API development, drug product manufacturing, and analytical services. Comparable vertically integrated small-molecule CDMO though operating at significantly larger scale.

Regional players

• Asymchem: Asymchem is a leading China-based small-molecule API and CDMO serving global pharmaceutical customers. Comparable in API synthesis capabilities and small-molecule focus, though geographically concentrated in Asia and competing primarily on cost rather than US domestic advantage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/apertus-pharmaceuticals

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apertus Pharmaceuticals